Status Epilepticus - Pipeline Insight, 2025

This “Status Epilepticus - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Status Epilepticus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Status Epilepticus: Understanding

Status Epilepticus: Overview

Status epilepticus (SE) is a medical emergency characterized by a prolonged seizure lasting more than 30 minutes or two or more seizures without regaining consciousness between them. It can be caused by various factors such as head trauma, stroke, brain tumors, or metabolic disorders. SE can lead to significant morbidity and mortality if not treated promptly. Treatment typically involves administering anticonvulsant medications such as benzodiazepines, phenytoin, or phenobarbital to stop the seizure activity. In severe cases, general anesthesia may be necessary to control the seizures.

Status epilepticus (SE) is characterized by continuous seizure activity or multiple seizures without recovery in between. Symptoms vary depending on the affected brain area and include generalized convulsive SE with rhythmic tonic-clonic seizure activity and impaired consciousness. Nonconvulsive SE manifests as repeated absence seizures or focal impaired awareness seizures, where the person is unresponsive without overt convulsions. Other symptoms can include temporary confusion, staring spells, stiff muscles. Status epilepticus (SE) is a life-threatening neurological emergency characterized by prolonged or repeated seizures without recovery between attacks. The pathology of SE involves complex physiological and biochemical changes that can lead to significant morbidity and mortality. SE can occur in patients with a history of epilepsy due to changes in medication or withdrawal syndrome, or it can be the initial manifestation of a seizure disorder. In patients without a history of epilepsy, SE is often related to underlying conditions such as hypoxia, metabolic derangements, toxicities, infections, or pregnancy-related complications.

Diagnosis of status epilepticus involves rapid clinical assessment to identify the type and cause of the seizures, along with laboratory tests to determine underlying factors. Electroencephalogram (EEG) monitoring is often employed to confirm ongoing seizure activity, especially in nonconvulsive status epilepticus where altered mental status is present without prominent motor movements. Prompt recognition and treatment are crucial to prevent permanent brain damage or death.

Treatment for status epilepticus requires immediate intervention to halt seizures and prevent brain damage. Initially, benzodiazepines such as lorazepam or diazepam are administered promptly at an adequate dose. If seizures persist beyond 5-20 minutes, second-line intravenous medications like phenytoin, fosphenytoin, levetiracetam, or valproic acid are used. For refractory status epilepticus unresponsive to these treatments, third-line anesthetic medications such as midazolam or barbiturates may be employed. Continuous EEG monitoring is essential to guide treatment and assess the patient's response. The primary goals are to quickly terminate seizures, stabilize the patient, and identify and address the underlying cause.

“Status Epilepticus - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Status Epilepticus pipeline landscape is provided which includes the disease overview and Status Epilepticus treatment guidelines. The assessment part of the report embraces, in depth Status Epilepticus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Status Epilepticus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Status Epilepticus R&D. The therapies under development are focused on novel approaches to treat/improve Status Epilepticus.

Status Epilepticus Emerging Drugs Chapters

This segment of the Status Epilepticus report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Status Epilepticus Emerging Drugs

Ganaxolone: Marinus Pharmaceuticals

Ganaxolone is a neuroactive steroid that works by modulating both synaptic and extrasynaptic GABAA receptors via a unique binding site to potentiate two types of inhibitory signaling. Ganaxolone has pharmacokinetic and pharmacodynamic properties well-suited for the treatment of status epilepticus, with rapid and sustained SE cessation observed in pre-clinical and clinical studies. Ganaxolone received orphan drug designation from the US Food and Drug Administration for the potential treatment of status epilepticus. The drug is currently being evaluated under Phase III clinical trial for the treatment of Status Epilepticus.

JBPOS0101: BioPharm Solutions

JBPOS0101 is an investigational small molecule drug being developed by BioPharm Solutions for the treatment of various neurological disorders, including epilepsy, infantile spasms, and Alzheimer's disease. JBPOS0101 is an antagonist of metabotropic glutamate receptors 1 and 7, which is believed to contribute to its broad-spectrum antiepileptic activity demonstrated in preclinical studies. Additionally, JBPOS0101 may have neuroprotective effects by modulating the blood-brain barrier, as shown in animal models of status epilepticus and other neurological insults. The drug has completed Phase I clinical trials and is currently in Phase II development for refractory epilepsy and infantile spasms.

Status Epilepticus: Therapeutic Assessment

This segment of the report provides insights about the different Status Epilepticus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Status Epilepticus

There are approx. 8+ key companies which are developing the therapies for Status Epilepticus. The companies which have their Status Epilepticus drug candidates in the most advanced stage, i.e. Phase III include Marinus Pharmaceuticals.

Phases

The report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Status Epilepticus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Status Epilepticus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Status Epilepticus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Status Epilepticus drugs.

Status Epilepticus Report Insights

• Status Epilepticus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Status Epilepticus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Status Epilepticus drugs?
• How many Status Epilepticus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Status Epilepticus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Status Epilepticus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Status Epilepticus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Marinus Pharmaceuticals
• BioPharm Solutions
• Jazz Pharmaceutical
• SciSparc

Key Products

• Ganaxolone
• JBPOS 0101
• Epidiolex
• SCI-210

This product will be delivered within 2 business days.